News

UK-based non-profit organization, Cystic Fibrosis Trust, recently launched a new awareness campaign that seeks to empower individuals living with cystic fibrosis (CF) to find out which specific CFTR gene mutation they are carrying. When patients know their specific mutation, physicians can prescribe more targeted, effective treatments, and even help patients participate in appropriate clinical…

A new report on cystic fibrosis (CF) in England and Wales further supports evidence of the groundbreaking impact that Kalydeco (ivacaftor) has had on treating CF, and reinforces the Cystic Fibrosis Trust‘s urgency for the drug to be made available to the 44 patients with rare CF gene mutations in…

The Cystic Fibrosis Foundation, a nonprofit donor-supported organization and world leader in the search for a cystic fibrosis cure, recently issued guidelines on the diagnosis and treatment of the disease. These guidelines were conceived by a committee of experts based on the available literature and clinical evidence reported.

The Food and Drug Administration has approved the use of the eRapid Nebulizer (eRapid) from Pari Respiratory Equipment Inc. to administer Genentech’s product Pulmozyme for use by patients with Cystic Fibrosis. Lisa Cambridge, the director of Medical Science and Pharmaceutical Alliances at Pari, described eRapid as, “a true…

Galapagos NV, a Belgium-based, clinical stage biotech company focused on developing novel mode of action medicines, recently announced it has received a €2.5 million grant from the Flemish Agency for Innovation through Science and Technology (IWT), which is meant to fund the company’s further research and development of new antibiotics. Working…